Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Mar 2022
Historique:
received: 11 01 2022
revised: 08 02 2022
accepted: 21 02 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 31 3 2022
Statut: epublish

Résumé

The B and T lymphocytes of the adaptive immune system are important for the control of most viral infections, including COVID-19. Identification of epitopes recognized by these cells is fundamental for understanding how the immune system detects and removes pathogens, and for antiviral vaccine design. Intriguingly, several cross-reactive T lymphocyte epitopes from SARS-CoV-2 with other betacoronaviruses responsible for the common cold have been identified. In addition, antibodies that cross-recognize the spike protein, but not the nucleoprotein (N protein), from different betacoronavirus have also been reported. Using a consensus of eight bioinformatic methods for predicting B-cell epitopes and the collection of experimentally detected epitopes for SARS-CoV and SARS-CoV-2, we identified four surface-exposed, conserved, and hypothetical antigenic regions that are exclusive of the N protein. These regions were analyzed using ELISA assays with two cohorts: SARS-CoV-2 infected patients and pre-COVID-19 samples. Here we describe four epitopes from SARS-CoV-2 N protein that are recognized by the humoral response from multiple individuals infected with COVID-19, and are conserved in other human coronaviruses. Three of these linear surface-exposed sequences and their peptide homologs in SARS-CoV-2 and HCoV-OC43 were also recognized by antibodies from pre-COVID-19 serum samples, indicating cross-reactivity of antibodies against coronavirus N proteins. Different conserved human coronaviruses (HCoVs) cross-reactive B epitopes against SARS-CoV-2 N protein are detected in a significant fraction of individuals not exposed to this pandemic virus. These results have potential clinical implications.

Identifiants

pubmed: 35328398
pii: ijms23062977
doi: 10.3390/ijms23062977
pmc: PMC8955325
pii:
doi:

Substances chimiques

Coronavirus Nucleocapsid Proteins 0
Epitopes, B-Lymphocyte 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministerio de Ciencia e Innovación
ID : COV20_00679 (MPY 222-20)
Organisme : Ministerio de Ciencia e Innovación
ID : MPY 509/19
Organisme : Ministerio de Ciencia e Innovación
ID : MPY 388/18

Références

EBioMedicine. 2020 Aug;58:102911
pubmed: 32711254
J Infect Dis. 2010 Oct 15;202(8):1171-80
pubmed: 20831383
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Chin Sci Bull. 2003;48(10):941-948
pubmed: 32214698
J Infect Dis. 2005 Jun 15;191(12):2033-7
pubmed: 15897988
Arch Virol. 2020 Dec;165(12):2829-2835
pubmed: 33000310
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
J Clin Pathol. 2006 May;59(5):468-76
pubmed: 16461566
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Viruses. 2018 May 02;10(5):
pubmed: 29724026
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9
pubmed: 15210961
Vaccines (Basel). 2020 Jul 20;8(3):
pubmed: 32698423
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Vaccines (Basel). 2021 Jan 11;9(1):
pubmed: 33440622
NPJ Vaccines. 2020 Mar 6;5(1):18
pubmed: 32194995
Elife. 2020 Apr 02;9:
pubmed: 32228860
J Clin Immunol. 2021 Jul;41(5):906-913
pubmed: 33725211
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W429-32
pubmed: 17483518
Virus Res. 2006 Dec;122(1-2):109-18
pubmed: 16942813
Emerg Infect Dis. 2004 Nov;10(11):1947-9
pubmed: 15550204
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Cell Rep Med. 2021 Jan 19;2(1):100189
pubmed: 33495758
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Virus Res. 2006 Dec;122(1-2):119-26
pubmed: 16920216
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2006-2011
pubmed: 32141569
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Nat Biotechnol. 2020 Jul;38(7):789-791
pubmed: 32504046
Clin Infect Dis. 2021 Apr 8;72(7):1291-1292
pubmed: 32445559
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147

Auteurs

Ana Tajuelo (A)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

Mireia López-Siles (M)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

Vicente Más (V)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

Pilar Pérez-Romero (P)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

José María Aguado (JM)

Hospital Universitario "12 de Octubre", 28041 Madrid, Spain.

Verónica Briz (V)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

Michael J McConnell (MJ)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

Antonio J Martín-Galiano (AJ)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

Daniel López (D)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH